Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.
Journal: Future oncology (London, England)
Published: November 23, 2022
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Journal: The New England journal of medicine
Published: December 08, 2015
Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma.
Journal: British journal of haematology
Published: January 07, 2015
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Journal: Nature medicine
Published: December 04, 2014
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Journal: Cancer chemotherapy and pharmacology
Published: June 26, 2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Journal: The New England journal of medicine
Published: June 03, 2014
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Journal: The New England journal of medicine
Published: June 21, 2013
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.
Journal: The Lancet. Oncology
Published: February 19, 2013
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 16, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026